BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Merck dazzled with Phase 3 trial results for its PAH drug WINREVAIR, but the market responded with a collective shrug, ...

Merck’s latest clinical data puts a shiny new needle on its cancer blockbuster Keytruda, showing that a quick two-minute ...

The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...

Despite the broader market downturn, 10 individual stocks showed a strong performance during the trading session, with three ...